Double Header Tonight: Proficient Alpha and Gig2 Expected to Price
by Kristi Marvin on 2019-05-29 at 1:13pm

Another $230 Million in SPAC Gross Proceeds Expected to Trade Tomorrow

Both Proficient Alpha (PAACU) and GigCapital2 (GIX.U) are expected to price their IPOs tonight to kick off the summer season and close out May. However, it’s already been a very busy year for SPACs.  In fact, it was only just last June that SPACs had seven IPOs price in one month for the first time since the Financial Crisis.  Since then, SPACs have priced seven IPOs in the months of August and October of 2018 and in February and March of 2019. If both Proficient Alpha and Gig2 price this week, we can add May 2019 to that distinction as well.

SPAC 2019 YTD Jan-May

However, will we see eight IPOs price in one month this summer to break the record?  June is unlikely. There aren’t enough on file right now, but there’s always July.  And don’t forget, while August is typically a slow month for the rest of the IPO market, SPACs don’t take vacations.  Eight is on the table.

Regardless, we have two more IPOs to get through this week and there is a better than average chance that both price tonight.  Proficient Alpha appears to be a lock (finally), whereas Gig2 is still a question mark.  However, Gig2 has gone ahead and filed their 8-a12b and their CERT (which is a signal that pricing is imminent) and the buzz is that they’re going to try bring this one over the finish line tonight instead of Thursday.

As you can see below, both deals are roughly the same size.  The only real structural differences are that Proficient Alpha is offering a Right and has a much shorter duration.  Albeit, Proficient is technically 18 months with their two 3-month extensions since there are no shareholder votes (and chances to redeem) in order to extend.  Additionally, Proficient is focusing on financial services in Asia/China, whereas Gig2 is focusing on technology, media, and telecommunications (TMT).

Based on structure, Proficient’s deal looks a little sweeter.  Plus, there’s also the issue of Gig1 still needing to close their combination before the Gig team embarks on a new SPAC (which you can read about HERE). That sort of muddied the waters for Gig2, regardless of how impressive the Gig team is.

As a reminder, summary IPO terms for both SPACs are below.

Proficient alpha and Gig2

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved